Carole Delauney
Senior Director Business Development

About

Carole Delauney was Senior Director Business Development at Swissfillon, and has continued to hold this position after the company’s acquisition by ten23 health in October 2021. She has also handled similar roles at small and large CDMOs based in Europe and the US since she started her career in 2003, with a focus on sterile fill-finish operations since 2007. Ms Delauney has a degree in Biochemistry from the University of Montpellier (France).

Contributions

WEARABLES

TECHNICAL CHALLENGES DURING THE DEVELOPMENT OF ON-BODY INJECTORS

Andrea Allmendinger, Michael Adler, Carole Delauney and Hanns-Christian Mahler provide an overview of large-volume wearable injection devices for the subcutaneous delivery of biologics and discuss the technical challenges associated with the development and manufacturing of these drug/device combination products.

More contributions

OCULAR

OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES

Rainer Glöckler, Carole Delauney, Dr Nicolas Eon and Katsuyuki Takeuchi discuss the myriad complexities of developing drug products for intravitreal injection, and how the partnership between swissfillon and Terumo can ease and accelerate these products to market. The first article, published in April, covered how swissfillon’s state-of-the-art filling line meets the complex requirements of ophthalmic drug products.

OCULAR

STATE-OF-THE-ART SOLUTIONS FOR OPHTHALMIC STERILE DRUG PRODUCT MANUFACTURING

In the first in a series of two articles, Rainer Glöckler and Carole Delauney discuss how the company’s state-of-the-art filling line meets the requirements and complexities that are particular to ophthalmic drug product manufacturing. The second article, to be published in May, will explore partnerships between pharma, CDMOs and syringe manufacturers in more detail.